Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 6;9:1817. doi: 10.3389/fimmu.2018.01817

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Schmid, Schneidawind, Jahnke, Kettemann, Secker, Duerr-Stoerzer, Keppeler, Kanz, Savage and Schneidawind.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dose-dependent kill of leukemia cell lines and patient leukemia cells by culture-expanded human invariant natural killer T (iNKT) cells. (A) Representative dot plots and specific lysis of MOLT-4 (92% 7-AAD- without iNKT cells) and Jurkat leukemia cells (87% 7-AAD- without iNKT cells) after co-incubation with culture-expanded iNKT cells. Each graph shows pooled data from four independent experiments with different culture-expanded iNKT cells. (B) Representative dot plots and specific lysis of AML M1 (88% 7-AAD- without iNKT cells) and AML M5 patient leukemia cells (89% 7-AAD- without iNKT cells) after co-incubation with culture-expanded HLA-mismatched iNKT cells. Each graph shows pooled data from four independent experiments with different culture-expanded iNKT cells tested against different patient AML cells. (C) Representative dot plots and specific lysis of patient leukemia cells (74 and 51% 7-AAD- without iNKT cells, respectively) after co-incubation with culture-expanded HLA-matched donor iNKT cells. Shown are two representative examples from three independent experiments. All events are gated on PBS57-loaded CD1d tetramer phycoerythrin negative cells to exclude iNKT cells. Error bars indicate SEM.

Dose-dependent kill of leukemia cell lines and patient leukemia cells by culture-expanded human invariant natural killer T (iNKT) cells. (A) Representative dot plots and specific lysis of MOLT-4 (92% 7-AAD- without iNKT cells) and Jurkat leukemia cells (87% 7-AAD- without iNKT cells) after co-incubation with culture-expanded iNKT cells. Each graph shows pooled data from four independent experiments with different culture-expanded iNKT cells. (B) Representative dot plots and specific lysis of AML M1 (88% 7-AAD- without iNKT cells) and AML M5 patient leukemia cells (89% 7-AAD- without iNKT cells) after co-incubation with culture-expanded HLA-mismatched iNKT cells. Each graph shows pooled data from four independent experiments with different culture-expanded iNKT cells tested against different patient AML cells. (C) Representative dot plots and specific lysis of patient leukemia cells (74 and 51% 7-AAD- without iNKT cells, respectively) after co-incubation with culture-expanded HLA-matched donor iNKT cells. Shown are two representative examples from three independent experiments. All events are gated on PBS57-loaded CD1d tetramer phycoerythrin negative cells to exclude iNKT cells. Error bars indicate SEM.